Compare Organon & Co. Common Stock (OGN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Smith & Nephew plc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Smith & Nephew plc trades at $28.24 (market cap $11.65B). The key difference: Smith & Nephew plc is far larger — about 3.2× Organon & Co. Common Stock's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Smith & Nephew plc for 121 Days on average.
| OGN | SNN | |
|---|---|---|
Market Cap | $3.61B | $11.65B |
Volume | 1,808,049 | 860,347 |
Sector | Health | Health |
52-Week High | $13.81 | $37.17 |
52-Week Low | $5.70 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $11.03B | $14.68B |
Dividend Yield | 0.58% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SNN trades at $27.86, near a 52-week low, with a mixed technical signal. Revenue has grown from $5.2B in 2022 to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches like the EVOS PELVIC System highlight innovation, but the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show steady growth and a reasonable P/E of 18.95, weak sentiment and technical pressure near lows suggest limited near-term upside. Risks include execution challenges and competitive threats, but long-term investors may find value if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
